Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Lypressin

FDA-approved product (solution, nasal), marketed as Diapid.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
4 of 4

Chemical structure

Chemical structure of Lypressin
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

No approved indication recorded

ChEMBL records no approved indication for Lypressin. Its therapeutic class is shown instead.

WHO therapeutic group
Vasopressin and analogues
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis, MRSA, E. coli and K. pneumoniae. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA63.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli55.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae48.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis59.3% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Lypressin in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Lypressin with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Terlipressin vs Placebo to Reduce Bleeding in Fibroid Surgery

    NCT07746349 · start 2026-08-01

    Registered record
    Registry ID
    NCT07746349
    Conditions
    Uterine Fibroids (Leiomyoma); Uterine Myoma; Leiomyoma
    Interventions
    terlipressin (vasoconstrictor); Placebo
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Not yet recruiting
    Start
    2026-08-01
    Completion
    2027-01
    Enrolment
    80

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionUterine Fibroids (Leiomyoma); Uterine Myoma; Leiomyoma
    Interventionterlipressin (vasoconstrictor); Placebo
    PhaseNot applicable
    Registry statusNot yet recruiting

  • Effects of Terlipressin and Somatostatin on Portal Pressure in Patients Undergoing Living Donor Liver Transplantation

    NCT07304466 · start 2025-12-29

    Registered record
    Registry ID
    NCT07304466
    Conditions
    Liver Transplantation; Portal Hypertension
    Interventions
    Somatostatin; Terlipressin
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Recruiting
    Start
    2025-12-29
    Completion
    2027-03-30
    Enrolment
    50

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLiver Transplantation; Portal Hypertension
    InterventionSomatostatin; Terlipressin
    PhaseNot applicable
    Registry statusRecruiting

  • Comparison of Terlipressin Versus Octreotide in Patients With Hepatorenal Syndrome

    NCT07460908 · start 2025-05-01

    Registered record
    Registry ID
    NCT07460908
    Conditions
    Hepatorenal Syndrome
    Interventions
    terlipressin; Octreotide (drug)
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2025-05-01
    Completion
    2025-10-30
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHepatorenal Syndrome
    Interventionterlipressin; Octreotide (drug)
    PhaseNot applicable
    Registry statusCompleted

  • Endothelin Receptor Antagonism With Ambrisentan to Treat Hepatorenal Syndrome

    NCT06256432 · start 2024-04-17

    Registered record
    Registry ID
    NCT06256432
    Conditions
    Hepatorenal Syndrome; Liver Cirrhosis; Acute Kidney Injury; Ascites Hepatic
    Interventions
    Ambrisentan; Terlipressin
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Active not recruiting
    Start
    2024-04-17
    Completion
    2026-06
    Enrolment
    54

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHepatorenal Syndrome; Liver Cirrhosis; Acute Kidney Injury; Ascites Hepatic
    InterventionAmbrisentan; Terlipressin
    PhasePhase 2
    Registry statusActive not recruiting

  • Intraoperative Continuous Terlipressin Infusion is Associated With Reduced Severe Postoperative Complications After Laparoscopic Hepatectomy: a Prospective Propensity Score-matched Cohort Study

    NCT07719933 · start 2024-04-01

    Registered record
    Registry ID
    NCT07719933
    Conditions
    Liver Neoplasms; Postoperative Complications
    Interventions
    terlipressin
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2024-04-01
    Completion
    2025-05-14
    Enrolment
    161

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLiver Neoplasms; Postoperative Complications
    Interventionterlipressin
    PhaseNot recorded
    Registry statusCompleted

  • Terlipressin in Combined Hepatorenal Syndrome in Patients With Signs of Chronic Renal Disease

    NCT06161766 · start 2024-03-03

    Registered record
    Registry ID
    NCT06161766
    Conditions
    Liver Cirrhosis; Hepato-Renal Syndrome; Chronic Kidney Diseases
    Interventions
    terlipressin or noradrenalin plus albumin
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2024-03-03
    Completion
    2024-12-31
    Enrolment
    490

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLiver Cirrhosis; Hepato-Renal Syndrome; Chronic Kidney Diseases
    Interventionterlipressin or noradrenalin plus albumin
    PhaseNot recorded
    Registry statusCompleted

  • Study to Evaluate R2R01 Plus Terlipressin Versus Terlipressin Alone in Patients With Hepatorenal Syndrome

    NCT05875948 · start 2023-06-30

    Registered record
    Registry ID
    NCT05875948
    Conditions
    Hepatorenal Syndrome; Acute Kidney Injury
    Interventions
    R2R01; Terlipressin
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2023-06-30
    Completion
    2024-12
    Enrolment
    95

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHepatorenal Syndrome; Acute Kidney Injury
    InterventionR2R01; Terlipressin
    PhasePhase 2
    Registry statusUnknown

  • Noradrenaline Versus Glypressin for Prevention of Hypotension After Deflation of Tourniquet in Knee Arthroplasty

    NCT05774067 · start 2022-12-01

    Registered record
    Registry ID
    NCT05774067
    Conditions
    Norepinephrine, Glypressin, Tourniquet Deflation; Hypotension
    Interventions
    Saline; Norepinephrine; glypressin
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2022-12-01
    Completion
    2023-07-30
    Enrolment
    135

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNorepinephrine, Glypressin, Tourniquet Deflation; Hypotension
    InterventionSaline; Norepinephrine; glypressin
    PhaseNot applicable
    Registry statusCompleted

  • Clinical Trial Comparing Noradrenaline (NA) Plus Placebo Versus Noradrenaline Plus Terlipressin (TP) in Septic Shock

    NCT05207280 · start 2022-10-11

    Registered record
    Registry ID
    NCT05207280
    Conditions
    Septic Shock
    Interventions
    Noradrenaline plus Terlipressin
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Unknown
    Start
    2022-10-11
    Completion
    2024-11
    Enrolment
    152

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSeptic Shock
    InterventionNoradrenaline plus Terlipressin
    PhasePhase 3
    Registry statusUnknown

  • ACid Tranexamic or Terlipressin for Initial Emergency Treatment of Mild to seVere hEmoptysis: a Randomized Trial.

    NCT04961528 · start 2022-03-27

    Registered record
    Registry ID
    NCT04961528
    Conditions
    Hemoptysis
    Interventions
    Tranexamic Acid 500 MG; Terlipressin; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2022-03-27
    Completion
    2026-03-25
    Enrolment
    315

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHemoptysis
    InterventionTranexamic Acid 500 MG; Terlipressin; Placebo
    PhasePhase 3
    Registry statusCompleted

  • The Effect of Intracapsular Injection of Terlipressin Versus Carbitocin on Hemoglobin and Blood Loss During Laparoscopic Myomectomy Operations

    NCT05170230 · start 2022-02-27

    Registered record
    Registry ID
    NCT05170230
    Conditions
    Myoma
    Interventions
    Terlipressin
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2022-02-27
    Completion
    2026-06-30
    Enrolment
    99

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMyoma
    InterventionTerlipressin
    PhaseNot applicable
    Registry statusUnknown

  • The Effect of Intramyometrial Injection of Terlipressin Versus Carbitocin on Hemoglobin and Blood Loss During Open Myomectomy Operations Using Haemostatic Tourniquets:

    NCT05242783 · start 2022-02-01

    Registered record
    Registry ID
    NCT05242783
    Conditions
    Myoma
    Interventions
    Terlipressin
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2022-02-01
    Completion
    2024-06-20
    Enrolment
    99

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMyoma
    InterventionTerlipressin
    PhaseNot applicable
    Registry statusCompleted

  • Comparison of Bolus Versus Continuous Infusion of Terlipressin Cirrhotic Patients With Septic Shock.

    NCT04819568 · start 2021-06-25

    Registered record
    Registry ID
    NCT04819568
    Conditions
    Liver Cirrhosis
    Interventions
    Terlipressin; Standard of Care
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2021-06-25
    Completion
    2022-03-19
    Enrolment
    310

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLiver Cirrhosis
    InterventionTerlipressin; Standard of Care
    PhaseNot applicable
    Registry statusUnknown

  • Terlipressin for HRS-AKI in Liver Transplant Candidates (INFUSE)

    NCT04460560 · start 2020-12-11

    Registered record
    Registry ID
    NCT04460560
    Conditions
    Hepatorenal Syndrome
    Interventions
    Terlipressin
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2020-12-11
    Completion
    2023-12-27
    Enrolment
    50

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHepatorenal Syndrome
    InterventionTerlipressin
    PhasePhase 3
    Registry statusCompleted

  • Efficacy of Early Terlipressin Plus Albumin Therapy in Comparison to Standard Treatment for HRS-AKI in Acute-on-chronic Liver Failure.

    NCT04416282 · start 2020-06-22

    Registered record
    Registry ID
    NCT04416282
    Conditions
    Acute-On-Chronic Liver Failure; Hepatorenal Syndrome; Acute Kidney Injury
    Interventions
    Terlipressin; Albumin
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2020-06-22
    Completion
    2022-06-10
    Enrolment
    70

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcute-On-Chronic Liver Failure; Hepatorenal Syndrome; Acute Kidney Injury
    InterventionTerlipressin; Albumin
    PhaseNot applicable
    Registry statusCompleted